The statements reached high consensus for considering GT for patients with TNBC and hormone receptor-positive (HR+)/HER2-negative eBC eligible for adjuvant poly (ADP-ribose) polymerase inhibitor (PARPi) treatment irrespective of age; considering age-based selection criteria for offering GT in case of no/limited family history of BC; and offering GT based on cancer recurrence risk. Here, NR4A1 is linked to cancer.